Comoros Technology Digest
SEE OTHER BRANDS

Get your science and technology news from Comoros

Comoros Technology Digest: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Comoros Technology Digest.

Press releases published on September 4, 2025

Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs) and small-molecule therapies for other ophthalmic …

Rocket Doctor Is Now In-Network for Aetna in New York State for Medicare and Commercial Health Insurance

Rocket Doctor Is Now In-Network for Aetna in New York State for Medicare and Commercial Health Insurance

     Rocket Doctor is now in-network with Aetna, having been fully credentialed for Medicare and Commercial insurance in New York State.      Aetna is one of the nation’s largest health insurers, covering 39 million members across 16 states.      Aetna …

AgEagle Aerial Systems MicaSense Series RedEdge-P Multispectral Camera Available Now on Ascent’s SPIRIT™ and SPARTAN™ UAV Platforms

AgEagle Aerial Systems MicaSense Series RedEdge-P Multispectral Camera Available Now on Ascent’s SPIRIT™ and SPARTAN™ UAV Platforms

Collaboration Delivers Best-In-Class Multispectral Sensor with Rugged, All-Weather VTOL Hardware to Advance UAS Capabilities in Agricultural and Research Applications WICHITA, Kan., Sept. 04, 2025 (GLOBE NEWSWIRE) -- AgEagle Aerial Systems Inc. (NYSE: UAVS …

Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation

Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation

Ongoing Phase 1b trial of GT-02287 to be extended by an additional nine months for participants who enrolled in the original three-month study design The independent data monitoring committee (DMC) met recently and recommended to continue the study with no …

MicroCloud Hologram Inc. (NASDAQ HOLO) Announces Robust Net Profit and Financial Results for the First Half of 2025

MicroCloud Hologram Inc. (NASDAQ HOLO) Announces Robust Net Profit and Financial Results for the First Half of 2025

SHENZHEN, China, Sept. 04, 2025 (GLOBE NEWSWIRE) -- MicroCloud Hologram Inc. reported a significant year-over-year turnaround to profitability in the first half of 2025. The Company's net profit for the first half of 2025 was RMB 238.1 million (US$33.1 …

Aeries Technology Announces Major Expansion Plans in India and Mexico, Adding 500 New Roles to Support Global Growth

Aeries Technology Announces Major Expansion Plans in India and Mexico, Adding 500 New Roles to Support Global Growth

NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Aeries Technology, Inc. (NASDAQ: AERT), a global leader in AI-powered business transformation and Global Capability Center (GCC) services, today announced ambitious growth plans to expand its talent footprint …

Roadzen Inc. Announces Strategic Equity Financing of Approximately $4.5 Million for Its India Subsidiary at an $84 Million Pre-Money Valuation

Roadzen Inc. Announces Strategic Equity Financing of Approximately $4.5 Million for Its India Subsidiary at an $84 Million Pre-Money Valuation

Raise anchored by marquee investors, including leading family offices and institutional investors in India. Values Roadzen’s India Subsidiary, contributing less than 60% of global revenues, at approximately a 25% premium to the Nasdaq-listed parent company …

dLocal Announces Pricing of Secondary Offering

dLocal Announces Pricing of Secondary Offering

MONTEVIDEO, Uruguay, Sept. 04, 2025 (GLOBE NEWSWIRE) -- DLocal Limited (“dLocal”), (NASDAQ:DLO) a technology-first payments platform, today announced the pricing of a previously announced secondary offering of 15,000,000 Class A common shares by an entity …

CorVista Health Announces Publication of Real-World Case Series in the Journal of the American College of Cardiology Exploring its Non-Invasive Test for Earlier Diagnosis of Pulmonary Hypertension

CorVista Health Announces Publication of Real-World Case Series in the Journal of the American College of Cardiology Exploring its Non-Invasive Test for Earlier Diagnosis of Pulmonary Hypertension

BETHESDA, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- CorVista Health today announced the publication of a new case series in the Journal of the American College of Cardiology (JACC), showcasing real-world clinical applications of the CorVista System®, a novel …

TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the H.C. Wainwright 27th Annual Global Investment Conference, …

Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)

Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)

New data from pre-specified analysis shows patients on concomitant miglustat who switched from placebo to MIPLYFFA experienced a decline in annual disease progression Nomination for Best Poster Award received for poster highlighting MIPLYFFA’s …

Digi Power X, Via Wholly-Owned Subsidiary US Data Centers Inc., Awarded Tier 3 ANSI/TIA-942-C “TIA-942 Ready” Certification for ARMS 200 AI Modular Platform

Digi Power X, Via Wholly-Owned Subsidiary US Data Centers Inc., Awarded Tier 3 ANSI/TIA-942-C “TIA-942 Ready” Certification for ARMS 200 AI Modular Platform

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated May 30, 2025 to its short form base shelf prospectus dated May 15, 2025. MIAMI, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Digi Power X Inc. (“ …

SAIC Announces Second Quarter of Fiscal Year 2026 Results

SAIC Announces Second Quarter of Fiscal Year 2026 Results

Revenues of $1.77 billion; approximately (3)% revenue contraction Net bookings of $2.6 billion; book-to-bill ratio of 1.5, trailing twelve months book-to-bill ratio of 1.0 Year-to-date net bookings of $5.0 billion; year-to-date book-to-bill ratio of 1.4 …

Immunocore to present at upcoming investor conferences

Immunocore to present at upcoming investor conferences

Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England …

Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)

Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)

BURLINGTON, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced the …

Hinge Bio Expands Leadership Team to Drive Clinical Development of GEM-DIMER™ Programs and Announces Publication in Scientific Reports

Hinge Bio Expands Leadership Team to Drive Clinical Development of GEM-DIMER™ Programs and Announces Publication in Scientific Reports

Paul Brunetta, M.D., joins as Chief Medical Officer; Kristen Quigley joins as Chief Clinical Operations Officer; Alpana Naresh, Ph.D., joins as Vice President and Head, CMC Strategy and Manufacturing Hinge Bio publishes differentiated in vivo data …

NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference

NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference

BELTSVILLE, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it …

Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025

Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025

WELLESLEY HILLS, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced details for the CLYM116 webcast event, which is set for …

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

WATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that its partner Biogen has had its …

Breckenridge Distillery and Denver Broncos Kick Off Fifth Year of Partnership with New Lineup of Spirits, Including Limited-Edition Broncos Honey Whiskey

Breckenridge Distillery and Denver Broncos Kick Off Fifth Year of Partnership with New Lineup of Spirits, Including Limited-Edition Broncos Honey Whiskey

BRECKENRIDGE, Colo., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Breckenridge Distillery, an award-winning craft distillery and spirits brand by Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY), is raising a glass to its fifth consecutive year as an official partner …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions